International Myeloma Foundation

Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth

Retrieved on: 
Thursday, April 4, 2024
Well, Organization, Bone marrow, Development, Learning, NLB, Walking, MAM, Disease, Empathy, Caregiver, Education, Patient, Social media, Research, Running, Hope, Wall, IMF, Quality of life, Marketing, International Myeloma Foundation, Huge, PFS, Human

“From South Korea to Portugal, India to Poland, all myeloma communities spoke as one voice once more for Myeloma Action Month!

Key Points: 
  • “From South Korea to Portugal, India to Poland, all myeloma communities spoke as one voice once more for Myeloma Action Month!
  • Beyond the numbers, this year’s #MyelomaACTIONMonth global campaign created ripples through the power of each myeloma story shared.
  • These ripples converged to create a mighty wave of awareness for multiple myeloma across the globe.
  • Sessions included Myeloma 101 & Understanding Your Labs, Financial Considerations in Myeloma, and Symptom Management and Living Well with Myeloma and much more.

Lifelong Philanthropist and 17-year Myeloma Survivor John O’Dwyer Elected to the International Myeloma Foundation’s Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Multiple myeloma, Pregnancy, Organization, Bone marrow, Development, Strategic planning, Disease, Patient, Celanese, Research, Cancer, University, IMF, Volunteering, Quality of life, United Way, Marketing, Woman, Black swan, International Myeloma Foundation, Thalidomide, MRD, International business, Loyola University Chicago, BSRI, Loyola University, Kellogg School of Management

STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.

Key Points: 
  • STUDIO CITY, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.
  • Prior to his recent election, John served on the IMF Board from 2010-2016 and made many significant contributions to advance the mission and goals of the IMF.
  • A cure is possible, but it is not free!”
    “I am thrilled to have John back on the IMF Board.
  • “I am very excited to welcome board member John O’Dwyer back to the IMF Board.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
BRAF, PD, Research, International Myeloma Foundation, Sale, Lung cancer, Workforce, Poster, Melanoma, P-value, Clinical trial, ATM, BCMA, Therapy, CCCC, Roche, Completeness, CRC, AACR, Conference, Colorectal cancer, Merck, NHL, Research and development, Cancer, Dexamethasone, Administration, Patient, Finance, Biogen, Pharmaceutical industry

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Key Points: 
  • As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
  • In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates.
  • Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022.

The International Myeloma Foundation Launches the Iceland Cycling Expedition: A Fundraiser to Advance the Goals of the iStopMM Project and the IMF’s Robust Array of Research Initiatives

Retrieved on: 
Tuesday, February 13, 2024
Knowledge, African Americans, Bone marrow, Research, Multiple myeloma, SMM, ICE, MGUS, IMF, International Myeloma Foundation, Genetic distance, University, Genetics, Blue, Blue Lagoon, DNA, Cryptocurrency

The ICE biking tour is an inaugural signature IMF Myeloma Cures fundraiser, with the goal of highlighting IMF’S diverse and robust research portfolio.

Key Points: 
  • The ICE biking tour is an inaugural signature IMF Myeloma Cures fundraiser, with the goal of highlighting IMF’S diverse and robust research portfolio.
  • Durie is elated that the Iceland Cycling Expedition will be inaugurated in Iceland—the home of the iStopMM Research Project.
  • To apply for this exciting expedition or to make donations, visit the IMF Iceland Cycling Expedition fundraiser.
  • The International Myeloma Foundation is grateful to Sanofi, a long-time and unwavering supporter of the IMF, for sponsoring the inaugural Iceland Cycling Expedition.

Trace Genomics CEO & Co-Founder Poornima Parameswaran Elected to the International Myeloma Foundation’s Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Agriculture, Soil, Genomics, Infection, Machine learning, University, Multiple myeloma, Stanford University, Purnima, DNA, Doctor of Philosophy, Patient, IMF, Science, Research, International Myeloma Foundation, Postgraduate education

LOS ANGELES, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation has recently announced the appointment of Dr. Poornima Parameswaran, the Chief Executive Officer, and Co-founder of Trace Genomics, to its board.

Key Points: 
  • LOS ANGELES, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation has recently announced the appointment of Dr. Poornima Parameswaran, the Chief Executive Officer, and Co-founder of Trace Genomics, to its board.
  • Her journey has been characterized by resilience, innovation, and a deep commitment to advancing science for a healthier planet.
  • As the CEO and Co-founder of Trace Genomics, Dr. Parameswaran is leading the charge in using DNA mapping to unlock the hidden potential of soil for sustainable agriculture.
  • Having experienced multiple myeloma as a patient, she has a deep understanding of the urgent need for innovative therapies and cures.

The International Myeloma Foundation (IMF) Welcomes Dr. S. Vincent Rajkumar as Chairperson of the Board

Retrieved on: 
Friday, February 2, 2024
Multiple myeloma, Clinical professor, Mayo Clinic, Jan, Research, Thalidomide, MD, Patient, Bone marrow, International Myeloma Foundation, IMF, Disease, Quality of life, European Journal, Education, Editor-in-chief

STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.

Key Points: 
  • STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.
  • He has published more than 480 peer-reviewed papers primarily in the field of multiple myeloma and related plasma cell disorders.
  • "I am very grateful that the IMF Board of Directors agreed to approve Dr. Rajkumar as the new IMF Chairperson of the Board when I decided not to seek re-election.
  • "We are thrilled to welcome Dr. S. Vincent Rajkumar as the new Board Chairperson of the International Myeloma Foundation.

Renowned Actor and Artist Ice-T Works Alongside the International Myeloma Foundation to Raise Awareness of Multiple Myeloma in the African American Community During Black History Month

Retrieved on: 
Thursday, February 1, 2024
Knowledge, Partnership, Multiple myeloma, African Americans, Transplant, Working, Survival, Research, Heart, Ice-T, News, Patient, Music, Incidence, Diagnosis, M-Power, International Myeloma Foundation, Bone marrow, Black History Month, IMF, White Americans, Disease, Quality of life, Multiple birth, Biology, Education, Health equity, Health, PSA

STUDIO CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Working alongside the International Myeloma Foundation (IMF), American songwriter, actor, producer, and well-known artist Ice-T is on a mission to help raise awareness of multiple myeloma in the African American community.

Key Points: 
  • STUDIO CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Working alongside the International Myeloma Foundation (IMF), American songwriter, actor, producer, and well-known artist Ice-T is on a mission to help raise awareness of multiple myeloma in the African American community.
  • In the U.S., 1 out of every 5 myeloma patients is African American—constituting about 20 percent of all myeloma patients.
  • These disparities are mostly caused by existing socioeconomic differences and barriers to healthcare access among African Americans with myeloma.
  • That’s why it’s so important to get the word out in the African American community to raise awareness about this lesser-known disease.

The International Myeloma Foundation Mourns the Passing of IMF Board Member Dr. Edith Mitchell

Retrieved on: 
Tuesday, January 23, 2024
Mentorship, Research, Principal, City, IMF, Internal medicine, AACR, Cancer, NCI, Public key certificate, FACC, Multiple myeloma, International Myeloma Foundation, National Cancer Institute, MACP, ECOG, African Americans, Medical college, Air force, National Medical Association, Breast, Health equity, Student, American Cancer Society, Radiation therapy, Thomas Jefferson University, Blue-ribbon committee, Military, NMA, Air National Guard, Human, FCPP, Oncology, Patient, Sadness, Partnership, ASCO, Distinguished Service Award, Friends, Society, Travel, LAPS, FRCP, Alpha Kappa Alpha, Clinical trial, Nursing

Dr. Edith Mitchell has been a member of the IMF Board of Directors for over twenty years.

Key Points: 
  • Dr. Edith Mitchell has been a member of the IMF Board of Directors for over twenty years.
  • In 2023, Dr. Mitchell received the Pennsylvania Medical Society’s (PAMED) Distinguished Service Award—the highest award presented by PAMED.
  • Edith Mitchell’s passing is such a profound loss for the IMF, the IMF Board of Directors, and the myeloma community at large.
  • The International Myeloma Foundation sends its deepest sympathies, thoughts, and prayers to Dr. Mitchell’s family members, friends, colleagues, and loved ones.

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Retrieved on: 
Tuesday, January 9, 2024
International Myeloma Foundation, Patient, PST, Therapy, Research, Conjugation, Melanoma, ATM, Biogen, Cancer, Drug discovery, PD, CCCC, Security, Multiple myeloma, DAC, Conference, Lung cancer, Webcast, Investigational New Drug, Workforce, Merck, BRAF, Colorectal cancer, Roche, EST, BCMA, Pharmaceutical industry

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies for patients. These priorities capitalize upon recent clinical data and key decisions, resulting in a sharpened focus on executing high-potential programs to ensure achievement of near-term milestones that position C4T for future success.

Key Points: 
  • As a result of this prioritized portfolio, C4T is restructuring its operations and reducing its workforce by approximately 30%.
  • C4T has strengthened its balance sheet to ensure sufficient runway to execute through and beyond critical value-inflecting clinical and discovery milestones.
  • “Building on recent momentum, we are well positioned to make meaningful advances across our portfolio in 2024.
  • Unaudited cash, cash equivalents and marketable securities as of January 5, 2024 were approximately $330 million.

argenx Highlights 2024 Strategic Priorities

Retrieved on: 
Monday, January 8, 2024
Immunoglobulin therapy, GMG, FDA, PRV, Congenital myasthenic syndrome, ARDA, Research Councils UK, Euronext, Inflammation, Cohort, PGIC, NRDL, Autoimmunity, Efgartigimod alfa, Dermatomyositis, Conference, MuSK protein, IND, CIDP, Pharmacokinetics, MMN, Safety, Therapy, Patient, ALS, Immune system, IL-6, Medicine, International Myeloma Foundation, IIP, FSS, Neonatal Fc receptor, Multifocal motor neuropathy, Growth, Pharmaceutical industry

argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.

Key Points: 
  • argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.
  • In addition, ARGX-119, a muscle-specific kinase (MuSK) agonist, will initiate Phase 1b/2a studies in congenital myasthenic syndrome and amyotrophic lateral sclerosis in 2024.
  • As of December 31, 2023, argenx had approximately $3.2 billion in cash, cash equivalents and current financial assets*.
  • Based on its current operating plans, argenx expects its combined R&D and SG&A expenses in 2024 to be less than $2 billion.